Two more drugs show promise against COVID-19 (2)

22 views

Skip to first unread message

Mark Crispin Miller

unread,

Apr 10, 2020, 12:31:10 PM4/10/20

to newsfromunderground

Two more drugs for "our free press" not to mention—along with the Japanese flu drug Avigen,

and Interferon Alfa-2B, developed and now widely marketed by Cuba—so as to clear the field

for the vaccine that Il Fauci and Bill Gates intend to see injected into every single one of us,

however we feel about it, whether we need it or not, and never mind what's really in it.

MCM

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Author links open overlay panelLeonCaly1 Julian D.Druce1 Mike G.Catton1 David A.Jans2 Kylie M.Wagstaff2

https://doi.org/10.1016/j.antiviral.2020.104787 t

Highlights

•: Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
•: A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture.
•: Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
•: Ivermectin is widely available, due to its inclusion on the WHO m

Click on the link for the rest.

Parasite Drug Shows Early Promise Against COVID-19

By Kathleen Doheny

April 7, 2020 -- An inexpensive drug used to treat parasitic infections killed the coronavirus that causes COVID-19 in less than 48 hours in a laboratory setting, Australian researchers say.

Best Practices for COVID-19

Play

Current Time0:00

0:35

Mute

Fullscreen

Progress: 0%

Best Practices for COVID-19

Practical tips to stop the spread of COVID-19.

ABOUT

The drug, ivermectin, has been used widely used for decades. It was introduced as a veterinary drug in the 1970s. Doctors also prescribe it to treat head lice, scabies, and other infections caused by parasites. According to a report published online in the journal Antiviral Research, the drug quickly prevented replication of SARS-CoV-2, the virus that causes COVID-19. The study has been peer-reviewed and accepted for publication, although it is not yet a "definitive" version of record.